Form 8-K - Current report:
SEC Accession No. 0001104659-24-098225
Filing Date
2024-09-09
Accepted
2024-09-09 17:11:02
Documents
13
Period of Report
2024-09-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2423567d1_8k.htm   iXBRL 8-K 25904
  Complete submission text file 0001104659-24-098225.txt   199338

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syn-20240906.xsd EX-101.SCH 3042
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20240906_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20240906_pre.xml EX-101.PRE 22378
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2423567d1_8k_htm.xml XML 3691
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 241287961
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)